Stifel analysts adjusted their outlook on CRISPR Therapeutics (NASDAQ:CRSP), currently trading at $43.09 with a market capitalization of $3.7 billion, reducing the price target to $49 from the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Stifel analysts reaffirmed their Buy rating on Generac Holdings (NYSE:GNRC) with a consistent price target of $210.00. Currently trading at $145.07 with a market capitalization of $8.63 billion, ...

Stifel Financial Corp. provides securities brokerage, investment banking, trading, investment advisory and related financial services. It operates through the following segments: Global Wealth ...

Proprietary Insights – Stifel Discover delivers exclusive analysis and commentary from Stifel’s Chief Investment Officer, Chief Economist, Chief Washington Policy Strategist, equity research analysts, ...

Good day and welcome to the Stifel Financial fourth quarter financial ... as well as the growth in commercial deposits enabled us to maintain deposit levels and avoid the impact of cash [sorting ...

Stifel Financial Corp. announced a cash dividend of $0.46 per share on its common stock, payable on March 17, 2025, to shareholders recorded by March 3, 2025. Additionally, the company declared ...

Stifel Bank and Stifel Bank & Trust offer a full range of consumer and commercial lending solutions. Stifel Trust Company, N.A. and Stifel Trust Company Delaware, N.A. offer trust and related ...

Stifel Financial Corp. (NYSE: SF) will release its fourth quarter and full year 2024 financial results before the market opens on Wednesday, January 29, 2025. The company will host a conference call ...